Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim report second quarter 2017

The leading Nordic fuel cell company PowerCell Sweden AB  (publ) presents interim report for Q2 2017. The company describes a continued increase in customer interest and a constantly increasing number of requests from companies wanting to test PowerCell's products and prototypes.The quarterly sales efforts and successful directed share issue, which included a capital injection of MSEK 225 before issue costs, confirms the transition of PowerCell: From a technically-oriented start-up company with focus on development, into an innovative commercial pioneering company

Clear improvement in production, but profitability remains a challenge

Q2-2017 (Q2-2016) · Gold production was 107.4 kg (73.7), with the increase driven by higher gold grade, improved production efficiency and increased tonnage · Milled ore was 47,621 tonnes (37,303) at head grade of 2.7 g/t (2.4) · Cash Cost was 1,124 USD/oz (1,396) · Revenue was 34.7 MSEK (20.9) · EBITDA was 0.5 MSEK (-4.8) · Profit after tax was -9.8 MSEK (-13.5) · Earnings per share was -0.93 SEK (-1.29) H1-2017 (H1-2016) · Gold production was 205.3 kg (132.2) · Milled ore was 88,425 tonnes (72,620) at head grade of 2.8 g/t (2.2) · Cash Cost was 1,162

Interim Report (January - June 2017)

January - June 2017Net sales amounted to SEK 903.8 million (847.4), a revenue growth of 6.7 percent. Adjusted for acquisitions and FX, the organic revenue growth amounted to 1.1 percent.Operating profit before depreciation and amortization (EBITDA) amounted to SEK 162.2 million (177.5), corresponding to an EBITDA margin of 17.9 percent (20.9), and 8.6 percent lower EBITDA compared to the corresponding period previous year.Net financial income/expense includes net foreign exchange differences of SEK -8.8 million (9.9).Profit for the period amounted to SEK 36.6 million (52.6).

INTERIM REPORT 1 APRIL – 30 JUNE, 2017

Second quarter 2017, compared to 2016, Group » Group net sales increased by 33% to SEK 622,897 (469,380) » Other operating income including capitalized development expenditure amounted to SEK 607,140 (381,298) » Loss before tax amounted to SEK –12,990,707 (–16,473,988) » Earnings per share (weighted average) amounted to SEK –0.45 (–1.03) Significant events during the second quarter   » Episurf Medical announced that the 50th implantation in Germany of the Episealer® knee implant was performed » Episurf Medical obtained further granted patents in Australia, US and Europe

Medivir initiates clinical study of birinapant in combination with KEYTRUDA® (pembrolizumab) in patients with treatment-refractory solid tumours

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the first patient has been enrolled in the company’s phase I/II study of birinapant in combination with the anti-PD-1 therapy KEYTRUDA® (pembrolizumab), which is marketed by MSD (known as Merck & Co., Inc, Kenilworth, NJ, USA in the US and Canada). The objectives of the study are to evaluate the safety, tolerability and preliminary efficacy of this combination in patients with treatment-resistant solid tumours.About the studyThe multicentre, single arm, open label study, which is primarily being run in the US,

Metsä Group's financial reporting in 2018

In 2018, Metsä Group will publish the following financial reports: Financial statements for 2017 8 February, Interim report for January–March 2018 3 May, Half year financial report for January–June 2018 2 August, Interim report for January–September 2018 8 NovemberMetsä Group Stock exchange release 18 August 2017 at 9.30 am EESTIn 2018, Metsä Group will publish the following financial reports: Financial statements for 2017                                        8 FebruaryInterim report for January–March 2018                           3 MayHalf year financial report for

INVISIO Interim Report January–June 2017: Growth initiatives for new products and sales offices

Stockholm, August 18, 2017 CEO comment”There has been a high level of activity in INVISIO in the first half of the year with continued growth initiatives to extend the product portfolio, increase the number of employees in research and development and increase market presence. Since last year we have opened two new offices and increased the number of employees by almost 50 per cent. The cost increases express our conviction that INVISIO can grow its sales considerably through these initiatives in the coming years”, says Lars Højgård Hansen, CEO of INVISIO.January–June 2017 ·

BioGaia AB Interim report 1 January – 30 June 2017

Comments from the Managing Director:“Sales in the second quarter of 2017 reached SEK 156 million, which is an increase of 15% compared to the same period of last year. The strong second quarter, when sales to our important market Brazil gained new momentum, meant that for the first six months we achieved sales of SEK 297 million, a gross margin of 75% and an operating profit of SEK 115 million. We are on the right track and continue with the implementation of our strategic initiatives. I am also very pleased that in the quarter we established the subsidiary BioGaia Pharma AB to take

Alma Media and Bauer Media start cooperation in radio news reporting

Alma Media Corporation                Press Release              18 August 2017 at 9.00 am ALMA MEDIA AND BAUER MEDIA START COOPERATION IN RADIO NEWS REPORTING In October, Iltalehti that belongs to the Alma News & Life business segment, will start to produce news broadcasts for Bauer Media’s biggest radio stations, Radio Nova and Iskelmä. The customised news to be produced for the stations will be broadcast every hour: on week days 17 times between 6 am and 10 pm and on weekends 15 times between 8 am and 10 pm. Radio Nova is Finland’s most popular commercial radio station with 1.3

Immunovia invites to a conference call on August 23, 2017

Immunovia invites to a conference call in connection with reporting the half-year results 2017. The conference call will take place at 16:00 on August 23 and the result is expected to be published at 8:30 AM the same day.The conference call, scheduled to last for a maximum of one hour, will be held in English. Following a presentation of the company by CEO Mats Grahn, we offer the opportunity to ask questions. Please call a few minutes before the conference call begins. Date: August 23, 2017Time: 16:00 (CET) Phone numbers:SE: +46 8 56642690CH: +41 225675548DE: +49 69222229046

JM acquiring property in Lund

JM has signed an agreement with Corem to acquire land for 560 building rights. The deal is worth SEK 270m. Occupancy and payment are expected to be completed in Q3 2017.The acquired property, which is part of Vipemöllan 38, is located in the eastern part of Lund. The property’s detailed plan has gained final approval for 560 apartments in a park environment. The area is next to the Hardeberga bike path and two kilometers from central Lund. The acquisition will be reported within the JM Residential Sweden business segment in Q3 2017.  “It is very gratifying to have signed an agreement

Tieto´s intelligent head office receives leading certificate for sustainability

At Tieto’s new head office in Keilalahti, Finland, every detail has been carefully thought of. Tieto Keilalahti Campus in Espoo has been designed to lift the employee experience to a new level, but also to go beyond the environmental requirements. Everything from energy consumption to the utilization rate of meeting rooms has been optimized. These solutions earned Tieto’s headquarters the first LEED platinum certificate for an existing building in Finland. Tieto’s sustainably re-designed office spaces in Keilalahti were built to support efficient and flexible ways of working, with open

Profitable growth and high level of ordersreceived

April – June 2017 ·  Operative net sales SEK 12,813 million (12,781) ·  Operative operating profit SEK 631 million (624) ·  Operative operating margin 4.9 percent (4.9) ·  Pre-tax profit SEK 623 million (609) ·  Earnings per share SEK 1.80 (1.74) ·  Orders received SEK 12,156 million (10,165) ·  Cash flow before financing SEK -1,105 million (6) January – June 2017 ·  Operative net sales SEK 23,909 million (21,473) ·  Operative operating profit SEK 947 million (812) ·  Operative operating margin 4.0 percent (3.8) ·  Pre-tax profit SEK 934 million (755)

Precise Biometrics strengthens management team with competence in business development

Fredrik Sjöholm, Senior Sales Director at Precise Biometrics with responsibility for sales and business development of new product areas, has been appointed to the management team.“Fredrik has extensive experience from sales and business development at international software companies and has particularly good knowledge about the Asian market where he also has worked locally. By bringing him in to the management team we strengthen the company's strategic business development”, said Håkan Persson, CEO of Precise Biometrics. Fredrik has many years’ experience from sales management and

Medivir licenses exclusive rights to MIV-802 for Greater China to Ascletis

Stockholm, Sweden and Hangzhou, China— Medivir AB (Nasdaq Stockholm: MVIR) and Ascletis today announce that Ascletis has licensed the exclusive rights to develop, manufacture and commercialize Medivir’s nucleotide polymerase inhibitor for hepatitis C, MIV-802 (Ascletis code: ASC21), in Greater China.Under the terms of the agreement, Medivir received an upfront payment, and is entitled to receive milestones based on successful development through commercial launch and tiered royalties on net sales of MIV-802 containing products. Ascletis will fund clinical development, manufacturing and

Nordnet first bank in Sweden with deposits through Swish

As the first bank in Sweden, Nordnet launches the possibility for customers to make deposits through Swish. During September, customers will be able to transfer money to their accounts in real-time and thereby translate their ideas into investments faster.Swish has grown rapidly in recent years, and is today used by 5.7 million people in Sweden. Now, Nordnet is the first Swedish bank to use Swish in order to offer its customers faster and easier deposits of money. -   Swish is easy to use, has high acceptance and a high level of trust, which is important when we talk about digital

Interim Report

January 1 – June 30, 2017The second quarter in figures · Net sales amounted to TSEK 2,046 (1,855). · The loss after tax amounted to TSEK 11,746 (14,468). · The loss per share amounted to SEK 1.42 (1.75). · The cash flow from current operations was negative in the amount of TSEK 11,044 (13,112). · The gross margin in the period was 34.2% (30.1%). The first 6 months in figures · Net sales amounted to TSEK 3,801 (2,921). · The loss after tax amounted to TSEK 23,358 (26,068). · The loss per share amounted to SEK 2.82 (3.15). · The cash flow from current

Isofols appoints Sven Erickson as Chief Commercial Officer

In preparation for partnering negotiations with pharma companies Isofol Medical AB (publ) announces the appointment of  Sven Erickson as Chief Commercial Officer. Mr. Erickson is an experienced life Science executive and brings to Isofol a track record of success in commercialization of pharmaceuticals, international license deals and marketing, spanning more than two decades.Isofol Medical AB (publ), a clinical stage oncology company about to enter a registration study within first line colorectal cancer treatment, announces the appointment of Sven Erickson as Chief Commercial Officer. He

Continued focus and consolidation

Second quarter: April-June 2017 · Operating revenue amounted to SEK 1,678 M (1,534), an increase of 9% or SEK 144 M. · Operating profit was SEK 74 M (56) including SEK 15 M in capital gain from sale of real estate.   · Net profit after tax for the period was SEK 48 M (34). · Earnings per share for the period before and after dilution were SEK 0.91 (0.64). · Operating cash flow was SEK 45 M (29).   · A dividend for the 2016 financial year of SEK 0.50 per share was approved at the 2017 Annual General Meeting, corresponding to approximately SEK 27 M. Interim period

Management change in Husqvarna Group

Sofia Axelsson, Senior Vice President, Group Communications, Brand & Marketing, has decided to leave the Group as of the end of September, 2017. Sofia Axelsson has been appointed President and CEO of Svedbergs i Dalstorp AB. "I want to thank Sofia for having built up the Group’s brand, marketing and corporate communication functions as well as for her valuable contributions in her other different positions during her time with the Husqvarna Group. I would also like to wish her the best of luck in the future”, says Kai Wärn, President and CEO of Husqvarna Group. The search for a

Nexam Chemical Holding AB (publ) Interim Financial Report 1 January – 30 June 2017

Sales record in the second quarterSecond quarter at a glance Operational: · The highest sales ever in the company´s history for a single quarter.   · Delivery completed to additional production facility at existing pipe customer at the same time as access to specific polyethylene is holding back volume growth. Alternative suppliers are under evaluation. · Funding from Vinnova granted for development of graphene-modified composites for long-term and high temperature applications together with SWEREA Sicomp. · Nexam Chemical approved for listing on Nasdaq First North Premier.

Nordic Mining’s interim report per 30 June 2017

Enclosed please find Nordic Mining’s interim report for the second quarter 2017.The interim report and company updates will be presented today, Friday 18 August 2017 at 10.00 in the company’s office at Vika Atrium, Munkedamsveien 45 (Entrance A, 5th floor), N-0250 Oslo.Important events in the second quarter 2017 and year-to-dateCorporate overview ·  Fully financed for planned development activities in 2017 ·  Value increasing feasibility studies well under wayThe ongoing feasibility studies for the Engebø rutile and garnet project (pre-feasibility study - PFS) and the

New Pathology Atlas maps the genes involved in cancer to accelerate progress in personalized cancer medicine

A new Pathology Atlas is launched today with an analysis of all human genes in all major cancers showing the consequence of their corresponding protein levels for overall patient survival. The difference in expression patterns of individual cancers observed in the study strongly reinforces the need for personalized cancer treatment based on precision medicine. In addition, the systems level approach used to construct the Pathology Atlas demonstrates the power of “big data” to change how medical research is performed.The dream of personalized treatment for cancer patients takes a major step

There are no items matching the current filter
There are no more items matching the current filter
Back to top